Trial Profile

A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMG 337 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Amgen

Most Recent Events

13 Nov 2018 Results published in the Clinical Cancer Research
22 Dec 2016 Status changed from active, no longer recruiting to completed.
21 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com